- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00373529
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.
This study will evaluate the efficacy of clofarabine in elderly patients with acute myelogenous leukemia (AML) who are unlikely to benefit from treatment with intensive chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients with AML.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten
- Mayo Clinical Hospital
-
Tucson, Arizona, Vereinigte Staaten
- Arizona Cancer Center
-
-
California
-
Los Angeles, California, Vereinigte Staaten
- USC/Norris Comprehensive Cancer Center and Hospital
-
San Diego, California, Vereinigte Staaten
- Scripps Cancer Center
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Southington, Connecticut, Vereinigte Staaten
- Cancer Center of Central Connecticut
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten
- Emory University School Of Medicine
-
Augusta, Georgia, Vereinigte Staaten
- Medical College of Georgia
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten
- Rush University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten
- University of Michigan Comprehensive Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten
- Mount Sinai School of Medicine
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten
- Oregon Health and Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten
- Penn State Hershey Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten
- University of MD Anderson Cancer Center
-
San Antonio, Texas, Vereinigte Staaten
- Cancer Care Centers of South Texas
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten
- University of Utah - Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten
- Seattle Cancer Care Alliance
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten
- West Virginia University - HSC
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder [AHD])
- Age ≥ 60 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following:
- t(8;21)(q22;q22)
- inv(16)(p13;q22 or t(16;16)(p13;q22)
- t(15;17)(q22;q12) and variants.
- Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation
- Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left ventricular fractional shortening ≥ 22%
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia
- Prior treatment with clofarabine
- Prior treatment for AML or an antecedent hematologic disorder
- Prior hematopoietic stem cell transplant (HSCT)
- Prior radiation therapy to the pelvis
- Investigational agent received within 30 days prior to the first dose of study drug
- Ongoing uncontrolled systemic infection
- Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
- Clinical evidence of central nervous system (CNS) involvement
- Severe concurrent medical condition or psychiatric disorder that would preclude study participation
- Positive human immunodeficiency virus (HIV) test
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Clofarabine
Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days.
Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
|
Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days. Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants Achieving Overall Remission (OR) After No More Than Two Cycles (Approximately Month 2)
Zeitfenster: approximately Month 2
|
Best response was assessed by the Independent Response Review Panel(IRRP) after two cycles of treatment.
Overall remission(OR) is the sum of complete remission(CR) and complete remission in the absence of platelet recovery(CRp).
CR includes normal values for peripheral blood cell counts (absolute neutrophil and platelet) and leukemic blast cells from bone marrow biopsy or aspirate, and absence of extramedullary disease.
Partial remission(PR) includes recovery of peripheral blood cells with improved but still abnormal values in leukemic blast cells.
|
approximately Month 2
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Kaplan Meier Estimate for Duration of Remission (DOR)
Zeitfenster: Up to 2 years
|
DOR was defined as the number of days from achievement of OR as assessed by the Independent Response Review Panel (IRRP) until IRRP-determined disease recurrence or death (any cause), plus 1 day.
Participants who initiated alternative antileukemic treatment while in remission were censored on the date the therapy was initiated or on the date of last follow-up.
|
Up to 2 years
|
Kaplan Meier Estimate for Disease-free Survival (DFS)
Zeitfenster: Up to 2 years
|
DFS was defined as the number of days from achievement of IRRP-determined overall response until IRRP-determined disease recurrence or death (any cause), regardless of intervening alternative antileukemic treatment, plus 1 day.
|
Up to 2 years
|
Kaplan Meier Estimates for Overall Survival (OS)
Zeitfenster: Up to 2 years
|
OS was defined as the number of days from first dose of clofarabine until death for all participants, plus 1 day.
|
Up to 2 years
|
Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment and Follow-up Periods
Zeitfenster: Up to 2 years
|
Participants with AEs that occurred during the treatment and follow-up periods. AEs were classified according to severity (graded using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 3.0) and relationship to study drug. Treatment emergent is defined as any event that either first presents after baseline or worsens in severity after baseline. NCI Common Terminology Criteria for Severity: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5= Death related to AE |
Up to 2 years
|
Percentage of Participants Who Died Within Thirty Days of Treatment (30-day Mortality Rate)
Zeitfenster: up to Day 30
|
Percentage of participants who died within 30 days of the first dose of study drug, regardless of cause.
|
up to Day 30
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants Achieving Overall Remission After A Maximum of Two Cycles by Subgroup of Baseline Prognostic Factors
Zeitfenster: approximately Month 2
|
The number of participants within each subgroup of baseline prognostic factors of the full analysis set who achieved a best response of either a complete response (CR) or a complete response in the absence of platelet recovery (CRp) as determined by the Independent Response Review Panel following a maximum of two cycles of treatment.
|
approximately Month 2
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLO24300606
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Akute myeloische Leukämie
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
-
Michael BurkeChildren's Hospitals and Clinics of MinnesotaBeendet
-
Sunshine Lake Pharma Co., Ltd.Rekrutierung
-
Azienda Ospedaliera Ospedale Infantile Regina Margherita...AbgeschlossenLeukämie, MyeloidItalien
-
Assistance Publique - Hôpitaux de ParisUnbekannt
-
Xuejie JiangRekrutierung
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendAkute myeloische Leukämie | Myeloisches Neoplasma | Myeloisches Sarkom | Leukämie cutisVereinigte Staaten, Kanada, Australien, Neuseeland, Puerto Rico
-
The Affiliated Hospital of the Chinese Academy...UnbekanntLeukämie, MyeloidChina
-
Virginia Commonwealth UniversityMassey Cancer CenterAbgeschlossenLeukämie | Myeloid | MonozytenVereinigte Staaten
Klinische Studien zur clofarabine
-
Omar MianRekrutierungAdenokarzinom | Karzinom | Metastasierender KrebsVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenAkute myeloische LeukämieVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenLeukämie, lymphoblastische, akute, pädiatrischeVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenSolide Tumore | Leukämie, myeloisch, akut, pädiatrisch | Leukemia, Lymphocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Adult | Leukemia, Myelocytic, Acute, Adult | Myelodysplastische Syndrome, ErwachseneVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenLeukämie, myeloisch, akut, pädiatrischVereinigte Staaten
-
Hannover Medical SchoolGenzyme, a Sanofi CompanyUnbekanntAkute myeloische Leukämie | MDBDeutschland
-
M.D. Anderson Cancer CenterGenzyme, a Sanofi CompanyZurückgezogenLeukämie | Chronischer lymphatischer LeukämieVereinigte Staaten
-
National Cancer Institute (NCI)RekrutierungNeubildungen | Myelodysplastische Syndrome | LymphomeVereinigte Staaten
-
UNC Lineberger Comprehensive Cancer CenterGenzyme, a Sanofi CompanyAbgeschlossenAkute myeloische Leukämie | Chronische myelomonozytäre Leukämie | Akute lymphatische Leukämie | Myelodysplastisches SyndromVereinigte Staaten
-
Fondazione Italiana Sindromi Mielodisplastiche-ETSZurückgezogenMyelodysplastische SyndromeItalien